DaVita Inc. (NYSE:DVA) Shares Sold by Patton Fund Management Inc.

Patton Fund Management Inc. lessened its position in DaVita Inc. (NYSE:DVA) by 5.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,872 shares of the company’s stock after selling 1,695 shares during the period. Patton Fund Management Inc.’s holdings in DaVita were worth $5,225,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Wedmont Private Capital increased its stake in DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after buying an additional 75 shares during the period. Blue Trust Inc. increased its stake in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the period. First Trust Direct Indexing L.P. increased its stake in DaVita by 3.9% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after buying an additional 98 shares during the period. Quent Capital LLC increased its stake in DaVita by 21.0% during the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after buying an additional 101 shares during the period. Finally, GAMMA Investing LLC increased its stake in DaVita by 18.8% during the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock valued at $91,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on DVA. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus target price of $159.00.

DaVita Trading Down 1.5 %

Shares of DVA traded down $2.39 during midday trading on Thursday, hitting $162.43. The stock had a trading volume of 167,417 shares, compared to its average volume of 806,755. DaVita Inc. has a fifty-two week low of $75.14 and a fifty-two week high of $168.50. The business has a 50-day simple moving average of $155.89 and a two-hundred day simple moving average of $144.28. The firm has a market cap of $13.63 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. During the same period last year, the company posted $2.08 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Insider Transactions at DaVita

In other news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock valued at $27,387,069 over the last three months. 2.00% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.